Regeneron Pharmaceuticals (REGN) Non-Current Deffered Revenue (2009 - 2026)

Regeneron Pharmaceuticals' Non-Current Deffered Revenue history runs 18 years deep, the most recent figure standing at $225.1 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue rose 6.28% year-over-year to $225.1 million; the TTM figure through Mar 2026 stood at $225.1 million (up 6.28% YoY), while the FY2025 annual figure was $208.7 million, up 12.39% from the prior year.
• Non-Current Deffered Revenue was $225.1 million for Q1 2026 at Regeneron Pharmaceuticals, up from $208.7 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $225.1 million in Q1 2026 to a low of $33.5 million in Q1 2022.
• Historically, Non-Current Deffered Revenue has averaged $148.9 million across 5 years, with a median of $185.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue dropped 4.77% in 2022, then jumped 155.22% in 2023.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $69.8 million in 2022, then jumped by 81.52% to $126.7 million in 2023, then soared by 46.57% to $185.7 million in 2024, then increased by 12.39% to $208.7 million in 2025, then rose by 7.86% to $225.1 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $225.1 million (Q1 2026), $208.7 million (Q4 2025), and $219.2 million (Q3 2025), per Business Quant data.